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Summary 
Genome-wide-association-studies have identified risk loci associated with the development of 
Inflammatory Bowel Disease while epidemiological studies have emphasized that pathogenesis 
likely involves host interactions with environmental elements whose source and structure need 
to be defined. Here, we identify a class of compounds, derived from dietary, microbial and 
industrial sources that are characterized by the presence of a 5-membered-oxazole-ring and 
induce CD1d-dependent intestinal inflammation. We observe minimal oxazole structures 
modulate natural killer T cell dependent inflammation by regulating lipid antigen presentation by 
CD1d on intestinal epithelial cells (IEC). CD1d-restricted production of interleukin 10 by IECs is 
limited through activity of the aryl hydrocarbon receptor (AhR) pathway in response to oxazole 
induction of tryptophan-metabolites such that depletion of the AhR in the intestinal epithelium 
abrogates oxazole-induced inflammation. In summary, we identify environmental derived 
oxazoles as triggers of CD1d-dependent intestinal inflammatory response that occur via 
activation of the AhR in the intestinal epithelium. 
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Introduction 
Inflammatory bowel disease (IBD) is a complex disorder that evolves from the interactions 
between poorly understood environmental factors and a host’s genetic framework that together 
define susceptibility to and severity of disease. Pathology is influenced by specific host 
elements that include the autochthonous commensal microbiota, which is acquired at birth, the 
intestinal epithelial cell barrier and subjacent immune cells within the intestinal mucosa (Kaser 
et al. 2010). One of the great challenges of understanding IBD pathogenesis stems from efforts 
to elucidate the molecular details surrounding the environmental basis for these disorders 
(Kaplan and Ng 2017). This is increasingly important since epidemiologic studies have revealed 
a rapid global expansion of these diseases that includes geographic regions, which have 
heretofore been unaffected (Molodecky and Kaplan 2010). 
A potential opportunity to investigate this question has emerged from recent studies on 
the role of CD1d and natural killer T cells (NKT) in mucosal biology. CD1d is a nonpolymorphic, 
major histocompatibility complex (MHC) class I-related molecule in non-covalent association 
with β2-microglobulin that presents cell associated and microbial lipid antigens to NKT cells 
(Barral and Brenner 2007). In the intestines, CD1d is expressed by parenchymal cells, such as 
the intestinal epithelial cell (IEC), and hematopoietic cells such as professional antigen 
presenting cells (APC) residing in the lamina propria (Brigl and Brenner 2004, RossJohn et al. 
2012, Van de waal et al 2003, Colgan et al. 1999, Dougan et al. 2007). CD1d-bearing IEC and 
APC present endogenous (self) or exogenous lipid antigens to NKT cells expressing an 
invariant T cell receptor (TCR) α chain (iNKT cells) or a semi-diverse (d) set of TCR-α chains 
(dNKT), which are present in human and mouse intestines (Brennan et al. 2013). 
Both types of NKT cells have been implicated in the pathogenesis of IBD through studies 
of human tissues and an experimental mouse model of IBD involving the chemical induction of 
colitis using a classic chemical hapten, oxazolone (Wirtz et al. 2007). Boirevant and colleagues 
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first demonstrated that administration of oxazolone directly to the colon in ethanol of SJL/J mice, 
or in later studies indirectly after skin painting and sensitization suggesting a model of 
haptenization, resulted in a severe acute, superficial inflammation due to the production of 
interleukin (IL)-4 and IL-13 that was counter-balanced by tumor growth factor-β which delimited 
the inflammation to the distal colon (Boirevant et al. 1998). This restriction to type 2 cytokines 
was eventually recognized to be genetically based as similar studies in C57Bl/6 mice revealed 
inflammation in association with oxazolone that was due to type 1 cytokines (namely interferon-
γ) derived from hematopoietic cells (Olszak et al. 2014, Iijima et al. 2004). In later 
groundbreaking studies by Heller and colleagues, it was recognized that oxazolone-induced 
colitis was dependent upon CD1d and iNKT cells as an inflammatory response to oxazolone 
was abrogated by the deletion of Cd1d or Jα18, encoding the invariant TCR-α chain (Heller et 
al. 2002). Moreover, the pro-inflammatory effects of CD1d-iNKT cell interactions in response to 
oxazolone were primarily derived from the activity of professional APC in the lamina propria 
using bone marrow chimeras (Olszak et al. 2014). In contrast, CD1d-expressing IECs were 
shown to secrete anti-inflammatory IL-10 in response to iNKT cells in a CD1d-dependent 
manner, which serves to restrain oxazolone-induced inflammation derived from the 
hematopoeitic system (Colgan et al. 1999, Olzsak et al. 2014). As such, when CD1d-restricted 
pathways in the IEC are specifically eliminated by conditional genetic deletion of Cd1d, 
microsomal triglyceride transfer protein (Mttp), an endoplasmic reticulum resident protein which 
serves to regulate CD1d lipidation and its ability to function, or Il10, oxazolone-induced colitis is 
unrestrained and severe (Dougan et al. 2005, 2007, Sagiv et al. 2007, Olszak et al. 2014). 
Human studies have further identified a potential role for dNKT cells in IBD by showing elevated 
IL-13 production by lamina propria mononuclear cells in response to sulfatide, a CD1d-restricted 
self-antigen which can activate iNKT and dNKT cells (Fuss et al. 2004, Fuss et al. 2014). 
Further, T cell receptor (TCR) transgenic mice expressing a non-invariant CD1d-restricted TCR 
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develop colitis (Wang et al. 2017). Moreover, some studies have shown that T cells expressing 
Vα24, the TCRAV chain expressed by iNKT cells, are increased in the intestinal mucosa and 
blood of patients with IBD; although others have reported the opposite observations suggesting 
a decrease of TCRAV bearing cells or their receptor upon activation (Fuss et al. 2004, Grose et 
al. 2007, van der Vliet et al. 2001). These studies together suggest that NKT cells may play a 
role in the pathogenesis of IBD.  
 Importantly, these host inflammatory responses to oxazolone occur even in animals 
raised under germ free (GF) conditions, indicating that NKT cell mediated response to self 
(rather than microbial) lipid antigens presented by CD1d on professional and/or non-
professional antigen presenting cells (APC) is sufficient for pathogenesis (Olszak et al. 2012). 
Instead, commensal bacteria themselves can modulate the magnitude of NKT cell responses 
either by directly altering the CD1d-restricted lipid antigen reservoir (An et al. 2014, Wieland 
Brown et al. 2013) or indirectly by regulating the quantity of iNKT cells in the colon (Olszak et al. 
2012). In the latter case, the absence of appropriate microbial signals in early life leads to 
elevated levels of iNKT cells in the colon that in later life makes the host susceptible to the 
colitogenic effects of oxazolone (Olszak et al. 2012). Conversely, CD1d itself plays a critical role 
in regulating the composition and extent of colonization by both commensal and pathogenic 
microbial species potentially through disruption of the anti-microbial activity of Paneth cells 
(Nieuwenhuis et al. 2005, Nieuwenhuis et al. 2009, Farin et al. 2014). 
The similarities between these biological observations in mouse models and current 
hypotheses for IBD pathogenesis wherein environmental triggers activate inflammation in a 
susceptible host lead us to hypothesize that oxazolone may be an example of a much larger 
collection of environmental chemical moieties capable of triggering CD1d-restricted iNKT cell 
responses. Consistent with this, we observe an abundance of oxazolone-related chemicals in 
the environment and microbiota capable of inducing intestinal inflammation. Specifically, we 
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have identified environmental mimetics of oxazolone that are derived from dietary, industrial or 
microbial sources which are characterized by the presence of a 5-membered oxazole ring and 
capable of driving CD1d-dependent inflammation through activation of the aryl hydrocarbon 
receptor pathway within IECs of the colon. As efforts to define and evaluate natural and 
synthetic chemicals involved in homeostasis or disease have generally been elusive, these 
results have broad implications for understanding the environmental basis of mucosal diseases 
such as IBD. 
Results 
Defining a structural moiety that modulates epithelial derived CD1d dependent 
inflammatory responses. 
4-ethoxymethylene-2-phenyl-2-oxazol-5-one, (referred to as oxazolone, Fig. 1A) has been 
widely utilized in models of contact hypersensitivity and when applied to the mucosa has been 
proposed to cause colitis through its properties as a hapten (Gorbachev and Fairchild 2001).  
However to date there is limited evidence for hapten-specific antibody production or responses 
following topical oxazolone sensitization or hapten modified autologous proteins or luminal 
antigens identified at mucosal sites (Singleton et al. 2016, Yanaba et al. 2008, Wirtz et al. 
2007). Interestingly, upon analysis of previously published microarray studies derived from 
epithelial enriched colon fractions following intra-rectal oxazolone challenge (Olszak et al. 
2014), we observed decreased transcripts for microsomal triglyceride transfer protein (Mttp, 
MTP) and increased transcripts for elements associated with aryl hydrocarbon receptor (AhR) 
signaling, including P450 enzymes (cyp1a1) and indoleamine 2,3-dioxygenase (Ido1). We 
therefore asked whether oxazolone could affect the expression of these transcripts in the 
intestinal epithelium in a cell intrinsic manner by directly stimulating an immortalized intestinal 
epithelial cell line (IEC) derived from mouse small intestine, MODE-K, with oxazolone. We 
observed down-regulation of Mttp and induction of metabolic genes cyp1a1 and Ido1 (Fig. 1B, 
S1A).  
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MTP is a critical regulator of mucosal homeostasis that promotes epithelial barrier activity by 
controlling CD1d-restricted IL-10 production by epithelial cells (Colgan et al. 1999, Olszak et al. 
2014). Thus IEC specific deletion of Mttp results in decreased CD1d-stimulated IL-10 production 
by the IEC leading to the exaggerated inflammatory activity of hematopoietic cells in response 
to oxazolone challenge resulting in increased colitis (Olszak et al. 2014). We therefore modeled 
interactions between NKT cells and IECs using MODE-K cells and CD1d-restricted T cell 
hybridomas in a previously described CD1d-dependent co-culture system (van de Wal et al. 
2003). These studies have shown that loading of CD1d with alpha-galactosyl ceramide (α-GC), 
a cognate lipid antigen, in this co-culture system, leads to MTP-dependent, CD1d-restricted IL-
10 production that is primarily derived from the IEC (Brozovic et al. 2004, Colgan et al. 1999, 
Olzsak et al. 2014). Here, we found that MODE-K cells pre-conditioned with oxazolone exhibited 
attenuated IL-10 production in response to α-GC when placed in co-culture with an iNKT cell 
hybridoma (24.7), which specifically reacts to α-GC presented on CD1d (Fig. 1C). Interestingly, 
epithelial derived IL-10 was also suppressed when IECs pre-conditioned with oxazolone were 
co-cultured with an autoreactive iNKT cell hybridoma (24.8) or an autoreactive non-invariant 
dNKT cell hybridoma (14S.6) in the absence of exogenously administered α-GC (Fig. S1B, 
S1C). These effects were specific to the IEC as co-culture of bone marrow-derived dendritic 
cells with the 24.7 iNKT cell hybridoma and α-GC lead to production of IFN-γ (Fig. S1D) but not 
IL-10 (data not shown) which was not affected by oxazolone or any of the oxazolone-related 
compounds described below. 
In light of the decreased MTP expression observed in oxazolone treated IECs (Fig. 1B) 
and given that MTP loss alters the ability of CD1d to acquire exogenous antigens, such as α-
GC, and CD1d elicited IL-10 responses by epithelial cells (Dougan et al. 2005, Dougan et al. 
2007, Zeissig et al 2017, Sagiv et al. 2007, Brozovic et al. 2004, Olszak et al. 2014), we 
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investigated CD1d expression and lipid loading on oxazolone conditioned IECs. IECs stimulated 
with oxazolone did not display altered CD1d protein expression or distribution between 
intracellular and cell surface pools (Fig. S2A, S2B), but instead exhibited decreased loading of 
α-GC on CD1d at the cell surface based upon staining with the CD1d-α-GC complex specific 
monoclonal antibody (L363) which revealed decreased mean fluorescence intensity on IECs 
exposed to oxazolone (Fig. 1D, 1E). These results were consistent with the decreased CD1d-
restricted IL-10 protein production we observed in MODE-K:iNKT cell co-cultures (Fig.1C, S1B, 
S1C), and suggest that oxazolone induced alterations in MTP expression were associated with 
decreased CD1d function affecting IL-10 production in response to iNKT cells, supporting 
previous observations of MTP activity in IEC (Dougan et al. 2005, Dougan et al. 2007).  
Oxazolone is administered in experimental models of colitis and contact sensitivity but is 
also widely used in industry and pharmaceuticals as a pharmacophore for the generation of 
synthetic compounds suggesting it may act as a potential environmental trigger of inflammation 
in sensitive hosts (Turchi 2008). We therefore sought to identify a library of structural mimetics 
of oxazolone and test whether these molecules behaved in a similar manner. We performed a 
two part in silico screen against three chemical databases of naturally occurring compounds 
(Human Metabolome Database, Super Natural II database, Dictionary of Natural Products) 
(Banerjee et al. 2015, Wishart et al. 2007) thereby limiting our search to compounds within a 
defined human envirome. Natural compounds were queried in the standard SMILES format and 
Tanimoto similarities between oxazolone and test compounds were computed with the 
ChemMine Similarity Workbench, which calculated maximum common substructure (MCS) 
similarities with the Tanimoto coefficient. Further, Euclidean distance scores were calculated 
using a non-continuous atom matching structural similarity function (NAMS) (Cao et al. 2008, 
Teixeira et al. 2013).  An initial screen identified 33 compounds with MCS >0.5 and Euclidean 
distance scores cutoff of 0.9 (Table S1). Oxazolone consists of four major functional moieties: a 
5-membered oxazole ring, a 2’ phenylgroup, a 4’ ethoxymethylene substituent, and the 5’-
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carbonyl lactone.  Our computational screen revealed the oxazole ring to be a distinctive and 
shared chemical sub-structure between the 33 compounds identified, all of which derived from 
dietary, microbial and/or industrial sources. We then employed a second screen using the same 
parameters but instead substituting a minimal oxazole ring as our template structure. The 
analysis led to the identification of 63 naturally occurring oxazole-containing (OxC) compounds 
(including the 33 described above), Of particular interest, we noticed that many of these 
compounds derived from three major sources: diet, microbes, and agriculture. This led us to 
determine whether oxazolone is a molecular prototype for a broader class of environmental 
stimuli that feature an oxazole sub-structure capable of modulating epithelial CD1d-restricted 
responses in a cell intrinsic manner. 
To test this, we devised a systematic in vitro system to assess transcriptional and CD1d-
restricted responses in IECs in response to stimulation with dietary OxC structures, including 
2,4,5-trimethyl-2,5-dihydro-1,3-oxazole (referred to as TMO, Fig. 1A) found in coffee, peanuts, 
meats and utilized as a food additive, which lacks the 2-phenyl ring, 5-ketone, and 4-
ethoxymethylene present in oxazolone (Vitzthum et al. 1975, Stoffesima et al. 1968, Lee et al. 
1981, Chang et al. 1968, Ho and Hartman 1968). Like oxazolone, TMO suppressed Mttp and 
induced cyp1a1 and Ido1 transcripts in IECs (Fig. 1B, S1). In contrast two structurally related 
non-OxC heterocyclic aromatic compounds 1,2,4-trimethyl cyclopentane (MCS=0.5, referred to 
as TMC) and 2-methyl-1-pyrroline (MCS=0.83, referred to as 1-MP), that substitute carbons at 
the 1’-oxygen and/or 3’-nitrogen, did not elicit any transcriptional changes in the target genes 
assessed (Fig. 1B).  Moreover, IECs conditioned with oxazolone or TMO but not TMC or 1-MP 
limited CD1d-restricted IL-10 production in co-cultures with an iNKT hybridoma (24.7) and the 
ability of CD1d to be lipidated with exogenously administered α-GC as revealed by decreased 
cell surface staining with the L363 monoclonal antibody (Fig. 1C, 1D, 1E). Overall, 5 of 7 tested 
naturally occurring dietary OxC as well as vinclozolin (Fig. 1A), an OxC fungicide used in 
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agriculture, phenocopied the transcriptional and CD1d-restricted epithelial responses observed 
after oxazolone stimulation.  
A minimal oxazole structure induces colonic inflammation in a CD1d dependent manner. 
We next asked if a dietary sourced minimal oxazole structure was sufficient to induce intestinal 
inflammation in vivo. Indeed intra-rectal administration of TMO was observed to lead to 
increased weight loss, colon shortening, and histological pathology characterized by superficial 
inflammation of the gut wall, neutrophil accumulation and ulceration of the epithelial layer of the 
colon that was similar to the inflammation associated with oxazolone (Fig. 1F, 1G, S3A) (Heller 
et al. 2002). The immune response to TMO but not 1,2,4-trimethylcyclopentane (TMC) or 
vehicle was characterized by production of Th2 and Th1 cytokines including IL-13 and IFN-γ 
from colon explants consistent with the genetic background of the hosts, C57Bl/6 (Fig. 1H) 
(Iijima et al. 2004). Importantly, intestinal inflammation after TMO challenge was dependent on 
the presence of iNKT cells, as CD1d-deficient animals displayed no evidence of clinical 
symptoms or pathology (Fig. 1F, 1G) as previously shown for oxazolone (Boirevant et al. 1998, 
Heller et al. 2002). In addition, the host in vivo IEC responses to TMO but not TMC or vehicle 
recapitulated the transcriptional changes observed in microarray and in vitro analyses including 
downregulation of Mttp and induction of cyp1a1 (Fig. S3B, S3C). Importantly, these studies 
were performed by direct administration of TMO to the colonic epithelium by rectal challenge 
without preceding skin sensitization further suggesting that the OxC-induced effects observed 
were direct and did not require prior immune activation as would be expected from a hapten-
induced model.  To confirm this, we compared the ability of oxazolone skin pre-sensitization to 
affect the responses to rectal challenge with TMO and vice-versa (Fig. S3D). These studies 
showed that pre-sensitization with oxazolone or TMO did not affect rectal responses to TMO or 
oxazolone, respectively; providing further evidence that oxazolone or TMO were having direct 
effects on the colonic mucosa.   
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A microbial derived oxazole structure modulates epithelial responses and leads to 
intestinal inflammation. 
Our in silico analysis also identified a class of bacterial derived toxins featuring oxazole moieties 
with a high degree of similarity to a minimal oxazole template. These are termed 
thiazole/oxazole modified microcins (TOMMs), a family of anti-microbial peptides featuring the 
presence of thiazol(in)e and oxazol(in)e heterocycles derived from cysteine, serine, and 
threonine residues on a ribosomally produced precursor peptide that confer a range of anti-
microbial activities including DNA gyrase inhibitors, translation inhibitors and hemolytic toxins 
(Table S1) (Melby et al. 2011, Collin et al. 2013, Vizan et al. 1991, Lee et al. 2008, Sassone-
Corsi et al. 2016). Though chemically and functionally diverse, as a rule TOMM biosynthetic 
gene clusters encode a leader peptide, enzymatic machinery including a cyclodehydratase and 
cyclodehydrogenase, that mediate post-translational installation of oxazole/thiazole moieties 
required for biological activity, and in some cases an immunity gene that protects the host strain 
from the anti-microbial activities of the TOMM itself (Melby et al. 2011).  Importantly, many 
TOMM biosynthetic gene clusters (BGC) have been described in a variety of human commensal 
communities as a means of providing host strains with ecological fitness advantages (Donia et 
al. 2014, Lee et al. 2008, Sassone-Corsi et al. 2016).  Within the commensal populations, these 
BGC encoded small molecule bacterial signaling factors collectively have an enormous potential 
to mediate microbe-microbe interactions (Donia et al. 2014, Wyatt et al. 2010, Nougayrede et al. 
2006, Mazmanian et al. 2005, 2008, An et al. 2014, Wieland-Brown et al. 2013, Yoshimoto et al.  
2013). Therefore, we considered it possible that microcins also regulated microbe-host 
interactions. We therefore asked whether oxazole containing microcin products modulated 
epithelial derived CD1d immune responses in the host as did other OxC compounds. To 
address this question, we focused our attention on Microcin B17 (MccB17, MCS=0.75), 
originally isolated from strains of Escherichia coli (E. coli) from the intestinal tract of newborns 
whose expression is linked to a plasmid (pMccB17) that carries a 7 gene mcb operon, encoding 
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the MccB17 toxin that acts as a DNA gyrase inhibitor (Table S1, Yorgey et al. 1994, Li et al. 
1996). The mcb operon was previously cloned into a pUC19 vector (Collin et al. 2013) and 
transformed into a competent E. coli BSL1 human commensal strain (MG1655). MccB17 
production is induced by growing bacteria in nutrient rich M63 media (Collin et al. 2013). 
Bacteria transformed with mcb17 or empty plasmid was grown in Luria Broth or M63 
supplemented media and bacterial lysates incubated with IECs after which we measured CD1d-
restricted responses upon co-culture with an iNKT cell hybridoma. We observed that lysates 
from bacterial isolates transformed with mcb and grown under MccB17 permissive conditions, 
but not non-transformed bacteria, attenuated CD1d-restricted IL-10 production in MODE-K:iNKT 
cell co-cultures, whereas lysates isolated from bacteria grown under non-permissive conditions 
or transformed with empty plasmid had no effect (Fig. 2A). To further examine whether 
suppression of CD1d-restricted responses was due to a MccB17 product, full length mature 
MccB17 was purified by High Performance Liquid Chromatography (HPLC) and examined in the 
aforementioned IEC:iNKT co-culture assay. To our surprise, purified MccB17 exerted no effects 
on CD1d dependent IL-10 production (Fig. 2B). However, although the full length MccB17 
microcin consists of a 3093 Da peptide, several smaller heterocyclic mcb17 derived heterocyclic 
species have been identified by MALDI-ToF mass spectrometry analysis which may or may not 
retain DNA gyrase inhibitory activity suggesting that the immunomodulatory effects of the 
MccB17 positive lysate might be a result of proteolytic and/or degradative products rather than 
the mature full length MccB17 itself (Collin et al. 2013, Sinha Roy et al. 1998). B17 microcin is 
sensitive to cleavage by subtilisin but not trypsin (Asensio and Perez-Diaz 1976). Therefore, we 
digested purified full length B17 with each protease and measured CD1d-restricted IL-10 
responses in the IEC:iNKT cell co-culture assay to these proteolytic products (Fig. 2B). In this 
case, cleavage products from subtilisin but not trypsin were able to attenuate IL-10 production in 
IEC:iNKT co-cultures with α-GC. Similarly, we observed decreased Mttp and induction of 
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Cyp1a1 transcripts in MODE-K cells incubated with MccB17 subtilisin proteolytic products but 
not full length B17 or MccB17 digested with trypsin (Fig. 2C).  
Taken together, these results suggested that the ability of MccB17 derived toxins to 
affect epithelial transcriptional and CD1d-restricted responses is limited by the size of the 
product. To clarify this size restriction, we screened a library of 8 synthetic MccB17 derived 
products with molecular weights ranging from 183.17-857.82 Da that are analogous to naturally 
produced MccB17 fragments and whose anti-DNA gyrase activity has been previously 
described (Fig. 2D) (Collin et al. 2013).  Consistent with our hypothesis, four fragments, 
containing permutations of 1 or 2 oxazole/thiazole moieties, with MW<270 Da were able to 
modulate CD1d dependent IL-10 production and regulate Mttp and Cyp1a1 whereas synthetic 
products >500Da were not (Fig. 2E, 2F and data not shown). Importantly, synthetic analogs 
capable of exerting immunomodulatory effects were within the relative size range of both 
oxazolone (217.22 Da) and 2,4,5-trimethyl-2,5,-dihydro-1,3-oxazole (113.16 Da) but surprisingly 
even synthetic products that did not confer anti-DNA gyrase activity were able to generate 
epithelial responses (Fig. 2D, 2E, 2F). Furthermore, both oxazole and thiazole containing 
compounds generated similar effects consistent with their shared physico-chemical properties 
(Fig. 2D, 2E, 2F). 
A synthetic B17 microcin derivative induces colonic inflammation in a CD1d-dependent 
manner independent of anti-microbial activity. 
We next asked whether B17 microcin derivatives could induce intestinal inflammation in vivo. 
We therefore synthesized adequate quantities of a minimal B17 derivative (termed frag-oz, Fig. 
2D) to perform in vivo experiments and challenged animals via intra-rectal administration. Like 
oxazolone and TMO, we observed CD1d-dependent pathology as well as induction of both Th1 
and Th2 cytokines from colon explants suggesting that this molecule induces inflammation in an 
iNKT dependent manner as inflammation and hematopoietic cell derived cytokine responses 
could be observed in WT, but not Cd1d-/- (CD1d KO), mice (Fig. 3A, 3B, 3C, S3A). We also 
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observed decreased Mttp levels and induction of Cyp1a1 in IEC enriched colonic fractions 
suggesting that frag-oz exerts immunomodulatory effects via the epithelial compartment in vivo 
(Fig. 3D. 3E). Though in vitro studies showed that frag-oz confers no anti-gyrase activity (Collin 
et al. 2013), to formally rule out the possibility that the intestinal inflammation observed was due 
to direct effects on the host rather than through its anti-microbial properties, we challenged GF 
and SPF mice with frag-oz or vehicle. Consistent with this, GF animals exhibited increased 
weight loss compared to animals raised under SPF conditions together with severe 
inflammation as defined by quantitative histopathology (Fig. 3C, 3F). These studies thus identify 
an oxazole containing microbial mimic that promotes CD1d-dependent intestinal inflammation 
independent of its classical anti-microbial activity. 
Activation of epithelial aryl hydrocarbon receptor pathways exacerbates responses to 
dietary and microbial oxazole compounds by limiting IL-10 responses. 
The data presented support a model in which exposure to a broad class of oxazole (or thiazole) 
ring containing compounds can direct transcriptional changes in responsive tissue 
compartments, such as the intestinal epithelium, that influence CD1d-restricted antigen 
presentation pathways resulting in compromised barrier integrity at mucosal sites, thereby 
augmenting iNKT (or non-invariant NKT) cell inflammatory responses, leading to colitis. These 
data also suggest the presence of cellular sensor(s) that are responsible for recognizing and 
transducing oxazole dependent signals. Review of our previous microarray analyses identified 
two signature aryl hydrocarbon receptor (AhR) targets, cyp1a1 and Ido1, involved in P450 and 
tryptophan metabolism, respectively, as inducible gene targets in the colonic epithelium (Olszak 
et al. 2014). Here we demonstrate that oxazolone, vinclozin, an industrial agent, and the dietary 
and microbial oxazole ligands, TMO and frag-oz, induced expression of these genes in vitro and 
in vivo. Interestingly, vinclozolin, an antifungal agent to which humans are exposed through 
agriculture and which affects CD1d-restricted pathways as an OxC as shown here, has been 
described as an AhR activator (Wambaugh et al. 2014, Dierickx 2004).  
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We therefore transfected IECs with an AhR firefly luciferase reporter and observed that 
oxazolone, TMO and 5 additional dietary oxazoles, as well as 4 synthetic MccB17 derivatives 
induced robust AhR transcriptional activity compared to vehicle or a non-oxazole heterocyclic 
control, 1,2,4-trimethylcyclopentane (Fig. 4A). Consistent with this, siRNA mediated knockdown 
of AhR in MODE-K cells abrogated induction of cyp1a1 and IDO1 and partially restored Mttp 
expression (Fig. S4A-C). Given that AhR regulates MTP expression we asked whether this 
pathway could modulate epithelial derived CD1d-restricted responses. Indeed, AhR deficiency 
caused by silencing AhR expression in epithelial cells reversed oxazolone, TMO or frag-oz 
induced inhibition of CD1d-restricted IL-10 production in IEC:iNKT cell co-cultures and reduction 
of cell surface CD1d lipid antigen loading (Fig. 4B, 4C). This was confirmed in hepatocytes 
obtained from Ahr-/- mice, which also exhibited resistance to the effects of oxazolone, TMO, frag-
oz or vinclozin induced inhibition of IL-10 production in response to iNKT cells in the presence of 
α-GC (Fig. S5). Interestingly, these effects were not attributed to general AhR function, but 
instead reflected a specific response to oxazole containing molecules as a human cognate AhR 
ligand, 2-(1H-Indol-3-carbonyl)-4-thiazolecarboxylic acid methyl ester (ITE), did not modulate 
Mttp expression or CD1d-restricted responses (Fig. 4B, 4C). 
These studies reveal a novel role for epithelial derived AhR signals in promoting 
mucosal inflammation when exposed to OxC. Consistent with this hypothesis, deletion of Ahr 
specifically in IECs (generated by crossing Ahrfl/fl to Villin-Cre transgenic animals, AhrΔIEC) 
resulted in elevated IL-10 production in colonic explants after oxazolone or frag-oz compared to 
wildtype controls (Fig. 4D), and conferred host protection to oxazolone (Fig. 4E, 4F) and frag-oz 
(Fig. 4G, 4H) after intra-rectal challenge as characterized by diminished weight loss and disease 
manifestations relative to that observed in Ahrfl/fl mice.  
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Oxazoles induce the generation of tryptophan derived metabolites that attenuate 
epithelial CD1d-restricted responses in an AhR dependent manner. 
Our studies show that although AhR regulates CD1d-restricted responses to oxazole containing 
compounds, this is not a property of all AhR ligands (such as ITE). This suggests that epithelial 
responses to OxC generate AhR agonists uniquely capable of attenuating IL-10 production 
through CD1d-restricted mechanisms. It was therefore of interest that we observed IDO1 
upregulation in IECs exposed to oxazoles (Fig. S1A). IDO1 is a rate-limiting enzyme involved in 
tryptophan catabolism that generates formyl-kynurenine which can be further metabolized into a 
variety of AhR agonists  (Higuchi and Hayaishi Arch Biochem Biophys 1967, Nguyen and 
Bradfield 2008, Zelante et al. 2014). Indeed, incubation of recombinant IDO1 with oxazolone, 
TMO or frag-oz enhanced the ability of IDO1 to convert tryptophan to formyl-kynurenine 
compared to control (TMC) or vehicle indicating that oxazole compounds may function to 
enhance IDO1 enzymatic activity through direct means (Fig. 5A).  To test whether tryptophan 
metabolism is therefore involved in the AhR effects we observed, we cultured IECs in 
tryptophan-deficient media and found that CD1d-restricted IL-10 production was no longer 
attenuated by stimulation with oxazolone, TMO or frag-oz when compared to TMC or vehicle 
controls (Fig. 5B). On the other hand, supplementation with exogeneous L-tryptophan (L-Trp) 
restored responses to oxazolone, TMO and frag-oz resulting in attenuation of CD1d-restricted 
IL-10 production supporting a role for tryptophan-derived metabolites in this process (Fig. 5B). 
To specifically identify these tryptophan derived products, we cultured IECs with deuterated L-
trp (D5-Trp) and performed high performance liquid chromatography mass spectrometry (LC-
MS) on lysates stimulated with oxazolone, TMO, frag-oz or TMC control (Fig. 5C). We detected 
uptake of D5-Trp in TMC stimulated IECs that was further metabolized to kynurenic acid and 3-
hydroxy kynurenic acid (referred to as xanthurenic acid) only upon stimulation with oxazolone or 
TMO and frag-oz, respectively, within 6 hours of exposure to oxazoles (Fig. 5C). To further 
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investigate whether tryptophan-derived metabolites attenuate CD1d-restricted responses, we 
cultured IECs in tryptophan-deficient media supplemented with L-Trp, kynurenic acid, 
xanthurenic acid, or an upstream tryptophan product, kynurenine, in the presence or absence of 
oxazolone. Supplementation with exogenous tryptophan or its downstream products of 
catabolism restored IEC responses to oxazolone as shown by reduced CD1d-restricted IL-10 
production (Fig. 5D). In contrast, supplementation with DL-methyl tryptophan (DL-Mtrp) a 
tryptophan competitive inhibitor of IDO1, did not restore suppression of CD1d-restricted IL-10 
production in IECs cultured in tryptophan-deficient conditions and stimulated with oxazolone 
(Fig. 5D). Finally, to ascertain whether these same metabolites identified in our LC-MS 
analyses, functioned through the AhR pathway, we performed siRNA-mediated knockdown of 
AhR in IECs cultured under tryptophan-deficient conditions in the presence of exogenously 
administered kynurenic acid and measured CD1d-restricted IL-10 production after stimulation 
with OxC compounds (Fig. 5E). Incubation of IECs with L-Trp or kynurenic acid alone or in 
conjunction with TMC stimulation had no effect on CD1d-restricted IL-10 production (Fig. 5B, 
5D). In contrast, IECs cultured under tryptophan-deficient conditions and stimulated with 
oxazolone, TMO or frag-oz when supplemented with kynurenic acid led to decreased IL-10 
production that was reduced when AhR was silenced (Fig. 5E). Taken together these latter 
studies are consistent with a model in which exposure of IECs to oxazole containing compounds 
leads to the activation of IDO1 and generation of tryptophan-derived metabolites that induce the 
AhR pathway to downregulate CD1d-restricted responses associated with the production of IL-
10 (Fig. 6).  
Discussion 
In the studies described herein, we have used structural analyses of oxazolone, a compound 
previously shown to be capable of inducing inflammation of the colon (Boirevant et al. 1998, 
Heller et al. 2002, Dietrich and Hess 1970), to identify a new and potentially broad class of 
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dietary, microbial, and other environmental derived factors within the human exposome (Melby 
et al. 2011, Wambaugh et al. 2014, Donia et al. 2014, Asensio and Perez-Diaz 1976). As shown 
here, these compounds are capable of direct induction of intestinal inflammation through 
crosstalk of CD1d-restricted and aryl hydrocarbon receptor pathways in intestinal epithelial cells. 
These structures, which we name oxazole-containing compounds (OxC), include a variety of 
chemicals used in agriculture (e.g. vinclozolin), food additives and processing (e.g. TMO) and 
microbial factors (e.g. bacterial microcins). In the latter case, we demonstrate that in addition to 
their well-established role as anti-microbial peptides, bacterial microcins are capable of inducing 
host responses. Together, this suggests that environmental agents capable of activating CD1d-
restricted pathways can do so by phenocopying host responses to microbial factors. In light of 
the wide presence of OxC in the environment including a number of microbial sources (Melby et 
al. 2011), these results have important implications for understanding potential environmental 
triggers that influence susceptibility to inflammation associated with the body surfaces 
associated with skin (e.g. dermatitis and contact hypersensitivity), intestines (e.g. IBD, allergy), 
esophagus (e.g. eosinophilic esophagitis), lungs (e.g. asthma) and potentially others that 
involve the activity of CD1d-restricted pathways in susceptible hosts at the body surfaces and 
perhaps elsewhere (Rossjohn et al. 2012, Nieuwenhuis et al. 2002, Lexmond et al. 2014, Leavy 
2006).  
Environmental and lifestyle factors have been identified as critical risk elements for 
development of disorders of chronic inflammation, such as IBD (Molodecky and Kaplan 2010). 
Consistent with this, chemical induced models of intestinal inflammation have been crucial 
experimental tools in investigating the pathophysiology and testing of therapeutic strategies for 
IBD. (Wirtz et al. 2007, Blumberg et al. 1999) Here, we have isolated the colitogenic activity 
within oxazolone to a five-membered heterocyclic oxazole moiety.  Based on these 
observations, we inquired whether oxazolone is representative of a broader class of 
environmental factors that may be involved in the pathogenesis of IBD and possess conserved 
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or shared sub-structure. Oxazolone, first synthesized in 1883 by Erlenmeyer and Ploechl (Plochl 
1884, Erlenmeyer 1893), has been widely utilized as a synthetic building block for compounds 
with a range of pharmacological properties including amino acids, antibiotics and 
pharmaceuticals (Kupera et al.  2011, Akram et al. 2014, Witvrouw et al. 1999, Sierra et al. 
2002, Madkour et al. 2002, Khan et al. 2006, Abdel et al. 2009). Oxazole ring containing 
compounds are also naturally abundant in diet as a component of many thermally processed 
foods including roasted coffee, roasted peanuts and heated beef or as flavor enhancers such as 
in fish products, as well as additives to fruits and vegetables through use of pesticides and 
fungicides, and contained in other environmental sources such as cigarette smoke (Vitzthum et 
al. 1975, Stoffesima et al. 1968, Lee et al. 1981, Chang et al. 1968, Ho and Hartman 1968). 
Previous epidemiologic studies have attempted to explore the relationship between food intake 
and IBD, and have shown varying associations between coffee, peanuts, meat intake, 
margarine and IBD (Barthel et al. 2015, Imanzadeh et al. 2015, Eaton et al. 2015, Hou et al. 
2011, Ng et al. 2015, Jowett et al. 2004). In addition, these studies have suggested that 
processed foods (in particular red meat and margarine) may be associated with colonic 
inflammation (Hou et al. 2011, Ng et al. 2015). However, dietary intake was predominantly 
measured from food recall diaries or weighted dietary records, and the mode of processing was 
not studied or discussed in detail in any of these studies. It would therefore be interesting to 
know if the positive associations observed were linked to oxazole-rich food compounds. The 
findings of our study certainly warrant more in-depth exploration of the association between 
intake of thermally processed, oxazole-rich foods and the incidence and prognosis of IBD as 
well as a variety of other allergic and inflammatory conditions that involve CD1d and NKT cells 
in their pathogenesis.  
In addition, microbes are another abundant source of oxazoles as part of a structurally 
functionally diverse class of ribosomally derived peptides dubbed thiazole/oxazole modified 
microcins (TOMMs) generated through post-translational installation of heterocycles derived 
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from cysteine, serine, and threonine residues. TOMMS are widely disseminated across the 
phylogenetic spectra of bacterial secretion systems, including potential pathobionts associated 
with IBD pathogenesis or skin inflammation including Bacteroidetes and Corynebacteriae, 
respectively (Melby et al. 2011, Bagley et al. 2005, Vizan et al. 1991, Carvalho et al. 2012, 
Mukhopadhya et al. 2012). Together, this supports the convergence of environmental and 
microbial derived chemical structures on conserved host immune responses. 
We observed that micromolar exposure to select oxazole species modulate CD1d-
restricted responses in epithelial cells in vitro which are characterized by down-regulation of 
Mttp and reduced IL-10 production after CD1d crosslinking with NKT cell associated receptors. 
This mechanism has been previously shown to reduce epithelial barrier activity in response to 
similar concentrations of oxazolone in the colon leading to exacerbated inflammatory responses 
(Olzsak et al. 2014). To what degree oxazole products accumulate within the intestinal tract and 
the physiological concentrations and circumstances required for triggering inflammatory 
responses are unknown. Interestingly, at least two of the structures we identified, 2,4,5-
trimethyl-1,3-dihydro-oxazole (TMO) and vinclozolin have been detected in human urine through 
studies associated with defining the human exposome (Table S1, Wambaugh et al. 2014). 
Although not directly addressed in this study, it is interesting to consider whether accumulated 
exposure to oxazoles derived from multifactorial sources, including diet, microbes, industry 
and/or agriculture acts in an additive or combinatorial manner that includes other potential non-
oxazole agents in modulating host responses that are associated with disease pathogenesis. 
Our gene expression profiling of intestinal epithelial cells exposed to oxazole compounds 
have identified a several genes (Fig 1B, 2C, 2F, 3E, S1A, S4) involved in xenobiotic metabolism 
and tryptophan catabolism, including indoleamine 2,3,dioxygenase 1 (IDO1), a marker highly 
expressed in patients suffering from IBD as well as in many animal models of colitis (Olszak et 
al. 2014, Barcelo-Batllori et al. 2002, Ferdinande et al. 2008, Dickgraefe et al. 2000, Wolf et al. 
2004, Hansen et al. 2009). Data presented here suggest that oxazole compounds enhance the 
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ability of IDO1, the rate-limiting enzyme in tryptophan catabolism, to metabolize tryptophan (Fig. 
5A). This supports a role for the aryl hydrocarbon receptor (AhR) as a potential cytosolic sensor 
or signal transducer of oxazole induced products in the intestinal epithelium (Nguyen and 
Bradfield 2008). Indeed, specific depletion of the AhR in the epithelium was shown to alleviate 
the oxazole-induced suppression of CD1d-restricted anti-inflammatory responses including 
production of IL-10 (Fig. 4B). Mass spectrometry analyses identified at least two products of 
tryptophan catabolism, kynurenic acid and xanthurenic acid, that are specifically generated in 
intestinal epithelial cells exposed to oxazolone or dietary and/or microbial oxazoles and their 
capacity to activate the AhR pathway in a manner that results in attenuation of CD1d-restricted 
IL-10 production. This observation is interesting given that levels of tryptophan and its 
byproducts in the serum have provided a robust marker for gastrointestinal pathology in clinical 
settings (Ciorba 2013). 
In the hematopoietic system, elevated IDO1 expression and subsequent AhR activation 
have been associated with immune tolerance implicating this pathway in maintaining intestinal 
homeostasis (Apetoh et al. 2010, Li et al. 2011, Gandhi et al. 2010, Kiss et al. 2011, Bessede et 
al. 2014, Veldhoen et al. 2008, Qui et al. 2012). Thus loss of AhR activity in hematopoietic cells 
can be deleterious resulting in decreased regulatory T cells or group 3 innate like lymphoid cells 
that together normally restrain inflammation, maintain intestinal epithelial barrier function 
through production of interleukin-22 (Apetoh et al. 2010, Li et al. 2011). Similarly, both IDO1 and 
AhR are highly expressed within the intestinal epithelial compartment, however their role in 
promoting or preventing intestinal inflammation is poorly understood (Ciorba 2013, Schiering et 
al. 2017, Lanis et al. 2017).  Here, we show that specific depletion of AhR within the intestinal 
epithelium, modulates CD1d-restricted responses in vitro and confers protection against the 
induction of intestinal pathology by oxazolone and a microbial oxazole compound in vivo (Fig. 
4F, 4H). These data implicate a novel role for AhR in regulating NKT cell lipid antigen sensing 
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specifically in IECs, which in contrast to the effects on the hematopoietic system (Apetoh et al. 
2010, Li et al. 2011), has a deleterious effect on the host in the context of colitis.  
In addition, we have shown that oxazoles also downregulate MTP that is normally 
responsible for the loading of phospholipid antigens onto CD1d (Dougan et al. 2005, 2007). 
Consistent with our observations, altering MTP expression or activity has been previously 
shown to prevent transfer of phospholipids to CD1d or the ability of CD1d to acquire exogenous 
lipid antigens such as α-GC (Dougan et al. 2005). Further, loss of MTP in IECs has been shown 
to disable the ability of iNKT cells to induce the barrier protective cytokine, IL-10, by this cell 
type as we have shown previously and demonstrated here (Olszak et al. 2014). Together, our 
data suggest that oxazoles alter presentation of lipid auto-antigens (Fig. S1B, S1C) and 
exogenous lipid antigens as shown with α-GC (Fig. 1D,1E, 4C) to CD1d-restricted invariant and 
non-invariant NKT cells in a pathway that is dependent on AhR through the generation of 
tryptophan-derived metabolites. As both oxazolone and frag-oz induce inflammation in animals 
under GF conditions (Olszak et al. 2012, Fig. 3D-E), NKT-mediated responses to host-derived 
lipid antigens may be particularly important to oxazole-induced inflammation and further suggest 
oxazoles may thus modulate autoimmune responses to self-lipid antigens.  
Conversely, it is also interesting to consider whether microbes use oxazole products to 
target CD1d in order to establish their niche during primary colonization potentially resulting in 
mucosal inflammation and pathology. Previous studies have demonstrated an important 
physiological role for CD1d during initial colonization of commensal and pathogenic bacteria 
(Nieuwenhuis et al. 2005, 2009). Specifically, CD1d-deficient animals re-derived and raised 
under GF conditions are unable to control colonization against gram-negative (Pseudomonas 
aeruginosa, Escherichia coli) and gram-positive (Staphylococcus auereus, Lactobacillus 
gasseri) bacteria. As a result, recently colonized CD1d-deficient GF animals exhibit an abnormal 
distribution of bacteria within the gastrointestinal tract and specific pathogen free, CD1d-
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deficient animals exhibit an altered composition of their microbiota relative to that observed in 
wildtype or heterozygotic littermates (Nieuwenhuis et al. 2009). Consequently, generation of 
products that modulate CD1d activity such as oxazoles, which are capable of specifically 
inhibiting intestinal epithelial cell function may affect the ability of microbes to colonize the 
intestine and potentially cause inflammation.  
Intestinal inflammation is often accompanied by microbial blooms, including 
Enterobacteria as compared to healthy intestine, potentially resulting in dysbiosis (Winter and 
Baumler Cell Microbiol. 2014, Ng et al. Nature 2013, Winter et al. Science 2013), which may be 
associated with production of certain microcins (Sassone-Corsi et al. Nature 2016). 
Interestingly, the MccB17 toxin, was initially isolated from human infants (Asensio and Perez-
Diaz 1976), and delineated as an inhibitor of DNA gyrases associated with gram-positive and 
gram-negative microbes (Roy 1999). Further, some low molecular weight fragments of MccB17 
isolated after bacterial lysis or generated by cleavage by microbial proteases retain their 
inhibitory activity while others lose their affinity for the MccB17 transporters, OmpF and SbmA 
and thus may accumulate in the intestinal lumen (Lavina J Gen. Microbiol 1986). We 
independently identified microcin compounds as modulators of host mediated CD1d-restricted 
epithelial responses based on their shared substructure with synthetic and dietary derived 
oxazoles. While full length MccB17 itself shared relatively low structural similarity with 
oxazolone, derivative products below 270Da generated either by alkaline hydrolysis or 
proteolytic cleavage showed relatively high similarity with both oxazolone and TMO (Table S1). 
Importantly we have observed that both the natural products and their synthetic analogs display 
similar ability to attenuate CD1d-lipid antigen presentation and subsequent CD1d-restricted IL-
10 production as well as activate AhR responses specifically in IECs resulting in inflammation 
associated with decreased epithelial derived IL-10. That inflammation to MccB17 derivatives 
occurs in GF animals confirms that the effects of these compounds are directly impacting the 
host and not a result of their anti-microbial capacity. It is therefore intriguing to consider then 
	   25	  
that the accumulation of oxazole compounds derived from MccB17 producing and other TOMM 
producing bacterial strains during a period of microbial competition may have a bystander effect 
on host immune responses resulting in intestinal inflammation or other effects that benefit the 
organism at the expense of the host.  
Our data also have interesting implications for understanding the biologic mechanisms 
by which so-called haptens mediate their effects. Classic immunologic studies using hapten-
carrier complexes have provided deep insights into concepts of B cell and T cell recognition of 
antigens and downstream immune responses to the hapten (e.g. oxazolone) or the protein 
carrier, which provides peptides for MHC class II presentation (Lemus and Karol 2008). Such 
pathways have been implicated in the pathogenesis of diseases such as contact 
hypersensitivity (Martin et al. Allergy 2011, Honda et al. J. Invest. Derm. 2013). Our studies 
indicate that chemical haptens may have important and direct biologic effects in their own right 
that could be a source of disease pathogenesis and/or modify other mechanisms.  Interestingly, 
we have found that oxazolone conjugated to a CD1d lipid antigen, α-GC, has no effect on α-GC 
CD1d binding or activity in vitro or in vivo (data not shown). Such insights may have important 
implications for interpreting models that use other chemical haptens (Wirtz et al. 2007). 
In conclusion, our studies illustrate a novel approach for interrogating triggers of 
inflammation due to environmental sources by searching for mimics of well-known chemical 
structures with established activities. In so doing, leveraging the knowledge available from 
oxazolone’s role as a colitogenic agent via modulation of CD1d-restricted pathways we have 
identified oxazole containing compounds (OxC) as a new class of potential environmental 
agents with inflammation inducing potential that are contained within a wide range of dietary, 
environmental and microbial sources. With respect to the latter, our studies further show that 
bacterial microcins, which are well known to play a role in microbe-microbe interactions, also 
possess important and previously unappreciated immune regulating properties via their effects 
on CD1d-restricted pathways. Further, in both the case of environmental and microbial OxC we 
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have found that they involve epithelial sensing by the AhR, which in turn adversely affects 
CD1d-restricted presentation of lipid antigens that are associated with barrier protective 
production of IL-10.  As a result, we also identified a novel pro-inflammatory activity of AhR 
sensing that is associated with the intestinal epithelium and have brought forth the concept that 
environmental triggers of inflammation that are potentially associated with IBD may function in 
this manner by phenocopying the activity of microbial products with similar activity. 
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Figure Legends 
Figure 1: A minimal oxazole structure modulates expression of specific gene targets and 
attenuates CD1d restricted in intestinal epithelial cells leading to colonic inflammation: 
A. Panel of oxazole containing and control heterocylic natural and synthetic compounds. B. 
Relative transcript abundance in MODE-K cells stimulated with indicated compounds, 
normalized to β-actin. C.  Interleukin 10 production in MODE-K cells conditioned with the 
indicated compounds, loaded with α-Galactosyl Ceramide (α-GC) followed by 24.7 iNKT 
hybridoma co-culture. D., E. Representative traces and quantification of surface CD1d loaded 
with α-GC in MODE-K cells conditioned with indicated compounds. F. Weight change after intra-
rectal administration of 1% TMO or EtOH (50% v/v) vehicle in wildtype (WT) or CD1d-deficient 
(KO) animals (n=16-20). *p<0.05 (Mann-Whitney U-test) G. Quantitative scoring for colitis after 
intra-rectal administration of 1% TMO or EtOH (50% v/v) vehicle in wildtype (WT) or CD1d-
deficient (KO) animals (n=8). H. Quantification (ELISA) of Interleukin 13 and IFN-γ production 
from colon explants 2 days after intra-rectal administration of 1% TMO, TMC or EtOH (50% v/v) 
vehicle (n=3). ** p<0.01 (Student’s t-test). *p<0.05 **p<0.01’ ***p<0.001 (Student’s t-test) 
Figure 2: Microbial derived oxazoles modulate CD1d restricted responses and regulate 
transcriptional targets in intestinal epithelial cells: Interleukin 10 response in MODE-K cells 
pre-conditioned with vehicle (DMSO) or indicated compounds: A. lysates from bacterial 
transformants (empty/pUC19, B17) grown in Luria Broth or M63 supplement, B. purified 
MccB17 (B17) microcin and/or B17 microcin proteolytic digest (subtilisin, trypsin), and 
subsequently loaded with α-GC followed by 24.7 iNKT hybridoma co-culture. C Relative 
transcript abundance of target genes, Mttp and Ido1, in MODE-K cells to β-actin in MODE-K 
pre-conditioned as in B. D.  Panel of synthetic analogs of B17 microcin proteolysis products with 
indicated anti-microbial activity. E. Interleukin 10 response in MODE-K cells pre-conditioned 
with vehicle, oxazolone, or synthetic MccB17 microcin analogs, and subsequently loaded with 
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α-GC followed by 24.7 iNKT hybridoma co-culture. F. Relative transcript abundance of target 
genes in MODE-K cells to β-actin in MODE-K pre-conditioned as in E. *p<0.05; **p<0.01; 
***p<0.001 (Student’s t-test). 
Figure 3: NKT cells are required for colonic inflammation induced by Frag-oz: A. 
Quantitative scoring for colitis after intra-rectal administration of 1% TMO or EtOH (50% v/v) 
vehicle in wildtype (WT) or CD1d-deficient (KO) littermates (n=8). B. Quantification of Interleukin 
13 and IFN-γ production in overnatant of colon explants 2 days after intra-rectal administration 
of 1% TMO or EtOH (50% v/v) vehicle (n=6) C. Weight change after intra-rectal administration 
of 1% Frag-oz or EtOH (50% v/v) vehicle in Germ Free or specific pathogen free animals (n=8). 
**p<0.01; ***p<0.001 (Mann-Whitney U-test). Quantification of D. Mttp and E. Cyp1a1 
transcripts (normalized to β-actin) from mucosal scraping 2 days after intra-rectal administration 
of 1% Frag-oz, or EtOH (50% v/v) vehicle (n=4). **p<0.01; ***p<0.001 (Student’s t-test) F. 
Quantitative scoring for colitis after intra-rectal administration of 1% TMO or EtOH (50% v/v) 
vehicle in germ free or specific pathogen free animals (n=8-9).  **p<0.01; p<0.001 (Student’s t-
test). 
Figure 4: Activation of Aryl Hydrocarbon Receptor by dietary and microbial derived 
oxazole compounds: A. Aryl Hydrocarbon Receptor promoter-reporter activity after MODE-K 
cells conditioned with indicated compounds. MODE-K cells transfected with scrambled (solid fill) 
or siRNA targeted against AhR (clear fill), conditioned with indicated compounds and then 
loaded with α-GC followed by 24.7 iNKT hybridoma co-culture B. Interleukin 10 production. C. 
Quantification of surface CD1d loaded with α-GC. D. Quantification of Interleukin 10 from 
overnatant of colon explants 3 days after intra-rectal administration of 1% oxazolone or 1% 
Frag-oz EtOH (50% v/v) vehicle in WT or animals with AhR-deficiency in epithelial compartment 
(AhrΔIEC). (n=4). Weight change after intra-rectal administration of E. 1% oxazolone or EtOH 
(50% v/v) vehicle or G. 1% Frag-oz or EtOH (50% v/v) vehicle in WT or animals with AhR-
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deficiency in epithelial compartment (AhrΔIEC). *** p<0.001 (Mann-Whitney U-test) F, H. 
Quantitative scoring for colitis after intra-rectal administration of oxazolone (F) or frag-oz (H) in 
EtOH (50% v/v) in WT or animals with AhR-deficiency in epithelial compartment (AhrΔIEC)  (N=5-
10). *p<0.05; ** p<0.01; ***p<0.001 (Student’s t-test). 
Figure 5: Oxazoles induce the generation of tryptophan derived metabolites that 
attenuate epithelial CD1d-restricted responses in an AhR dependent manner: A. 
Recombinant IDO1 was incubated with L-tryptophan in the presence of oxazole (oxazolone, 
TMO, Frag-oz), control (TMC) compounds or vehicle and formyl-kynurenine production 
measured via a calorimetric assay, B. MODE-K cells cultured with L-tryptophan deficient media 
or media supplemented with exogenous L-tryptophan and CD1d-restricted Interleukin 10 
responses measured in MODE-K cells pre-conditioned with vehicle or indicated compounds. C. 
LC-MS quantification of label retaining metabolites in MODE-K cells grown under tryptophan 
deficient conditions and supplemented with deuterated tryptophan and conditioned with the 
indicated compounds. D. CD1d-restricted Interleukin 10 responses in MODE-K cells pre-
conditioned with vehicle or oxazolone in tryptophan deficient media with supplementation with L-
tryptophan, DL-methyl tryptophan, kynurenine, kynurenic acid, or xanthurenic acid and then 
loaded with α-GC followed by 24.7 iNKT hybridoma co-culture. E. CD1d-restricted Interleukin 10 
production by MODE-K cells transfected with scrambled (solid fill) or siRNA targeted against 
AhR (clear fill) in tryptophan deficient media. CD1d-restricted Interleukin 10 responses were 
measured following pre-conditioning with vehicle, TMC, oxazolone, TMO or frag-oz with or 
without supplementation of L-tryptophan or kynurenic acid.  ***p<0.001 (Student’s t-test). 
Figure 6. Exposure to environmental oxazoles (from diet or microbes) influences CD1d-
restricted responses in intestinal epithelial cells through production of tryptophan 
derivatives that activate the aryl hydrocarbon receptor pathway.  Intestinal epithelial cells 
(IEC) promote mucosal barrier protection through microsomal triglyceride protein (MTP) 
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mediated CD1d-restricted production of Interleukin 10 (IL-10, blue circles). Upon exposure to 
oxazole compounds (derived from diet, microbes or other environmental sources), these CD1d-
restricted responses are attenuated through a mechanism involving the production of tryptophan 
derived metabolites (kynurenic acid, xanthurenic acid, orange squares), through the activity of 
IDO1, that trigger the aryl hydrocarbon receptor (AhR). Decreased, CD1d-restricted IL-10 
production results in unrestrained inflammatory responses (IL-13/IFNγ, red dots) and resulting 
pathology.  ER (endoplasmic reticulum), IFN-γ (Interferon γ). 
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STAR Methods 
 
Contact for Reagent and Resource Sharing 
Further information and requests of reagents can be directed to and fulfilled by the Lead 
Contact, Dr. Richard S. Blumberg (BLUMBERG@BWH.HARVARD.EDU). 
 
Experimental Model and Subject Details 
Animals 
Mice (C57Bl/6J) were housed in a specific pathogen-free (SPF) barrier facility at Harvard 
Medical School: Wildtype, Ahrfl/fl, Villin-Cre, mice were purchased from The Jackson Laboratory. 
Ahr-/- mice were purchased from Taconic USA and maintained as heterozygotes. Cd1d1-/-Cd1d2-
/- have been described (Exley et al. 2003). Animal studies were conducted in a gender and age 
matched (8-10 week) manner using littermates for each experiment, except for wildtype versus 
Cd1d-/- comparisons. SPF and Germ-free animals were bred and maintained in vinyl isolators in 
the Harvard Digestive Disease Center Gnotobiotic and Microbiology Core. For colitis 
experiments, mice were transferred to Optimice cages (Animal Care Systems) for daily 
monitoring under sterile conditions. All procedures were approved by the Harvard Medical Area 
Standing Committee on Animals.	  
Primary Cultures 
Bone marrow derived cells (BMDC) were purified from mouse femurs and cultured for 7 days in 
RPMI (supplemented with 10% fetal bovine serum, 1% antibiotic-antimycotic, Gibco and 20 
ng/mL granulocyte-macrophage colon-stimulating factor, Biosource). For primary hepatocyte 
isolation, mice were anesthetized with intraperitoneal injection of ketamine (87 mg/kg body 
weight) plus xylazine (13 mg/kg body weight), after which the inferior vena cava was exposed, 
cannulated and perfused for 5 min with liver perfusion media (Invitrogen), followed by a 10 min 
perfusion with liver digestion media (Invitrogen). The digested liver was minced in hepatocyte 
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was media (Invitrogen) and cells were pelleted and resuspended in Williams E medium (10% 
FBS, 10-7M dexamethasone, 10 µg/ml insulin and 5 µg/ml transferrin.  
Bacterial Stocks and Purification  
MccB17 was generated and purified as described (Collin et al. 2013, Li et al. 1996). Plasmid 
pUC19, wild-type or carrying the complete biosynthetic operon (mcbABCDEFG), was 
transformed into competent DH5α or MG1655 E. coli.  
Synthesis of Microcin B17 and Derivatives 
Overnight colonies were grown in LB media and used to inoculate M63 media (3 g/l KH2PO4, 7 
g/l K2HPO4, 2 g/l (NH4)SO4, 1 mM MgSO4, 1 µg/ml thiamine, 0.2% glucose, 0.1 mg/ml ampicillin) 
or LB Media (0.1mg/mL ampicillin) and incubated for 48 h. Cells were pelleted and lysed in a 
boiling solution of 1 mM EDTA and 100 mM acetic acid. Cellular debris was removed by 
centrifugation, protein was quantified by BCA Assay kit (ThermoFisher Scientific) according to 
manufacturer’s instructions and lysates were serially titrated (1µg-10µg/mL) incubated with 
MODE-K cells for co-culture assays as described. Digestion of full length MccB17 (a gift from A. 
Maxwell, Collin et al. 2013) by subtilisin (Sigma) (0.1 mM MccB17, 10% DMSO, 10 mM NaAcO, 
5 mM Ca(AcO)2) or sequence grade trypsin (Promega) (0.5 mM 50 µg/mL trypsin, 1%DMSO in 
buffer (Promega) for 24 h to completion (Collin et al. 2013). Entire digested products (or 
equivalent buffer with enzyme) was then incubated with MODE-K cells for co-culture and qPCR 
analyses.	  
Synthesis of Frag-oz 
Frag-oz, frag-tz, frag-oztz, and frag-tzoz originally were kindly provided by R. Payne, School of 
Chemistry University of Sydney or later synthesized by A.L. The compounds were synthesized 
according to established procedures for microcin B17-related oxazole and thiazole synthesis 
(Videnov et al. 1996). 
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Refer to Figure S6A. Step 1. Synthesis of 2-(aminomethyl)oxazole-4-carboxamide (Fig S6A) 
Tert-butyl ((4-carbamoyloxazol-2-yl)methyl)carbamate 11 (0.895 g, 3.71 mmol)  was stirred in 
TFA/CH2Cl2 (1:1 v/v, 40 mL) at room temperature for 1 h. The solvent was removed under 
reduced pressure affording the title compound as a brown oil (0.367g, 70%). 1H NMR (400 MHz, 
Methanol-d4) δ 8.42 (s, 1H), 4.28 (s, 2H). Step 2. 2-(acetamidomethyl)oxazole-4-carboxamide 
(Frag-oz): To a solution of 2-(aminomethyl)oxazole-4-carboxamide 2 (630mg, 4.46 mmol) in 
DMF (2.2 mL) at 0ºC TEA (0.7 mL, 4.9 mmol) was added followed by Acetyl Chloride (0.35 mL, 
4.9 mmol). The solution was stirred for 5 h at 0ºC. The DMF was removed under reduced 
pressure and the crude product was purified by column chromatography on silica [DCM-
Methanol, 9:1 (v/v)] affording the title compound as a white solid (400mg, 49%). 1H NMR (400 
MHz, Methanol-d4) δ 8.30 (s, 1H), 4.48 (s, 2H), 1.99 (s, 3H). 13C NMR (101 MHz, Methanol-d4) δ 
172.12 , 163.71 , 161.52 , 142.01 , 135.76 , 35.87 , 20.92. 
Tert-butyl ((4-carbamoylthiazol-2-yl)methyl)carbamate (4) 
Aqueous ammonia (28% w/w, 3,1 mL, 40 mmol) was added to a solution of ethyl 2-(((tert-
butoxycarbonyl)amino)methyl)thiazole-4-carboxylate2 3 (381 mg, 1.33 mmol)  in methanol (1,3 
mL). After 16 h at 45ºC, the reaction mixture was concentrated affording the title compound as a 
brown oil (315mg, 92%) which was used directñy in the next step. 1H NMR (400 MHz, Methanol-
d4) δ 8.10 (s, 1H), 4.49 (s, 2H), 1.45 (s, 9H). 
2-(aminomethyl)thiazole-4-carboxamide (5) 
Tert-butyl ((4-carbamoylthiazol-2-yl)methyl)carbamate 4 (0.342 g, 1.331 mmol) was stirred in 
TFA/CH2Cl2 (1:1 v/v, 13 mL) at room temperature for 1.5 h. The solvent was removed under 
reduced pressure affording the title compound as a green oil (0.150, 72%) which was used 
directly in the next step. 1H NMR (400 MHz, Methanol-d4) δ 8.25 (s, 1H), 4.41 (s, 2H). 
Synthesis of Frag-tz 2-(acetamidomethyl)thiazole-4-carboxamide 
Refer to Fig. S6B. To a solution of 2-(aminomethyl)thiazole-4-carboxamide 5 (204mg, 1.30 
mmol) in DMF (6.5mL) at 0ºC, Triethylamine (TEA , 0.2 mL, 1.43 mmol) was added followed by 
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Acetyl Chloride (0.1 mL, 1.43 mM). The solution was stirred for 5 h at 0ºC. The solvent was 
removed 
under reduced pressure and the crude product was purified by column chromatography on silica 
[CH2Cl2 /Methanol, 9:1 (v/v)] affording the title compound as a white solid (80mg, 31%). 1H NMR 
(400 MHz, Methanol-d4) δ 8.11 (s, 1H), 4.63 (s, 2H), 2.01 (s, 3H). 13C NMR (101 MHz, 
Methanol-d4) δ 172.13 , 169.43 , 164.11 , 149.10 , 124.41 , 40.47 , 21.01. 
Method Details 
Experimental colitis model 
For reciprocal sensitization studies (Fig. S3), mice were pre-sensitized by epicutaneous 
application of 3% w/v oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma-Aldrich) 
or 2,4,5-trimethyl-2,5-dihydro-1,3-oxazole (Sigma-Aldrich) in 100% ethanol (200  L volume). 
Five days later, animals were re-challenged intra-rectally (through a 3.5F catheter) with 1% 
vehicle, oxazolone or 2,4,5-trimethyl-2,5-dihydro-1,3-oxazole in 50% ethanol (5  L/g of body 
weight) as indicated. For all other studies, vehicle, oxazolone, 2,4,5-trimethyl-2,5-dihydro-1,3-
oxazole, 1,2,4-trimethylcyclopentane (Sigma-Aldrich) were administered intra-rectally (through a 
3.5F catheter) as a 1% solution in 50% ethanol (5 µl/g of body weight). Body weight, rectal 
bleeding, and stool consistency were analyzed 1-2 times daily. Tissues obtained at the indicated 
time points were embedded in paraffin, stained with hematoxylin and eosin, and examined by a 
pathologist (Dr. Jon Glickman) in a blinded fashion for evidence of colitis according to five 
established criteria: mononuclear inflammation, crypt hyperplasia, epithelial injury, neutrophilic 
inflammation, and hypervascularization grading on 4 point scale (0=absent, 1=mild, 
2=moderate, 3=severe).   
Colon organ culture 
Standardized segments (1 cm × 1 cm) of the transverse colon were washed in cold PBS 
supplemented with penicillin and streptomycin (GIBCO) and cultured in 24-well flat-bottom 
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culture plates (Falcon) in RPMI 1640 media (GIBCO) for 24 h at 37°C. Supernatants were 
analyzed for cytokines IL-10, IL-13 and IL-1β by ELISA (all BD). 
Cells and Antigen presentation assays 
1 x 105 BMDCs, primary hepatocytes or 0.5 x 105 MODE-K cells (Vidal et al. 1993) were 
incubated in 96 well plates (Corning) maintained in RPMI (supplemented with 2% fetal bovine 
serum, 1% antibiotic-antimycotic, Gibco) were pulsed with the indicated compounds dissolved in 
dimethyl sulfoxide (DMSO) at a concentration of 10  M for 36-48h. Cells were washed three 
times with sterile phosphate buffered saline (PBS, Gibco) after which cells were incubated with 
100 ng ml-1 alpha-galactosyl ceramide/KRN7000 or beta-glucosyl ceramide (Avanti Polar Lipids) 
for 3h, washed three times with sterile PBS, before addition of 2 x 104 NKT hybridoma cells 
including 24.7, 24.8, and 14S6  overnight co-culture after which supernatant was collected and 
clarified by centrifugation. Mouse IL-10, IFN  production was assessed by ELISA (OptEIA, BD 
Biosciences). For aryl hydrocarbon receptor siRNA mediated knockdown, MODE-K cells were 
transfected with AM100441, AM 100360, or Silencer negative control siRNAs (ThermoFisher 
Scientific) using Lipofectamine 2000 (Life Technologies) according to manufacturer’s 
instructions. AhR silencing was verified 48h after transfection by quantitative polymerase chain 
reaction. 
Identification of Tryptophan Derived Metabolites 
MODE-K cells were cultured in dialyzed FBS and RPMI (Gibco #26400044, RPMI 1640 cGMP 
#100001229, all amino acids <1nM, ) and supplemented with essential amino acids (histidine, 
isoleucine, leucine, lysine, methionine, phenylalanine, threonine, and valine at 1µM) and 
supplemented with deuterated tryptophan (1 µM D5-Trp, Santa Cruz sc-391262, see Key 
Resources Table). Lysates were extracted from cell pellets in 80% Methanol and analyzed with 
reverse phase HPLC-MS (Agilent C18 column connected with Thermo Scientific LTQ-XL, see 
Key Resources Table). 
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IDO1 enzymatic assay 
Recombinant His-tagged IDO1 was incubated with 10nM concentrations of TMC, oxazolone, 
TMO, or frag-oz and assay was performed according to the manufacturer’s instruction (BPS 
Bioscience, San Diego, CA, see Key Resources Table) 
CD1d and CD1d-lipid complex measurements by flow cytometry. 
MODE-K cells were pulsed with 10 µM indicated compounds dissolved in DMSO for 36-48h. 
Cells were washed three times with sterile PBS after which cells were incubated with 100 ng ml-
1 alpha-galactosyl ceramide/KRN7000 or the non-agonistic compound, beta-glucosyl ceramide 
(data not shown), for 3 h, washed three times with sterile PBS. Cells were lifted in 10 mM 
EDTA/PBS and stained with the following antibodies: mouse L363 (eBiosciences, see Key 
Resources Table), mouse CD1d (BD Bioscience, see Key Resources Table). For intracellular 
staining, cells were fixed using the Intracellular Fixation and Permeabilization Buffer Set 
(eBioscience, see Key Resources Table) according to the manufacturer’s instructions. Flow 
cytometry was performed on MACSQuant Analyzer (Miltenyi Biotec) and analyzed using FlowJo 
software. 
Quantitative polymerase chain reaction assays 
RNA samples were prepared using an RNeasy Mini Kit and cDNAs were synthesized using the 
Omniscript RT Kit (Qiagen, see Key Resources Table). Real-time RT–PCR was performed using 
SYBR Green I Master Mix (Roche) and a CFX96 Real-Time System (Bio-Rad, see Key 
Resources Table). Values were normalized to β-actin (see Key Resources Table).  
Luciferase promoter-reporter assays 
 For aryl hydrocarbon receptor luciferase assays, MODE-K cells were cultured on 6-well plates 
(Corning). pGL4.43 Luc2pXRE (Promega) or empty pGL4.43 (Promega) and 100 ng Renilla 
luciferase (Promega) was transfected into MODE-K cells using Lipofectamine 2000. Twenty four 
hours later, MODE-K cells were conditioned with indicated compounds for 48 h. Cells were 
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lysed and firefly luciferase (normalized to renilla luciferase) was measured using Dual 
Luciferase Reporter Assay System (Promega) 
In-silico similarity screening 
We used two-step in-silico screening process. First, broad similarity screening was performed to 
identify oxazole related natural compounds from various databases including Pubchem, Super 
Natural II a database of natural products (Bannerjee et al. 2015), Dictionary of natural products 
Chemnet database, and The Human Metabolome Database (Wishart et al. 2013) (Table S1). 
Second, focused screen search was performed based on the results of first screening to identify 
natural compounds related to a 5-membered oxazole ring of oxazolone with emphasis to find 
minimal structural features of oxazolone for its inflammatory activity. This focused screen 
selection was based on identification of natural compounds with Tanimoto similarity of more 
than 0.5 and/or Euclidean distance scores cutoff of 0.9 (Table S1). Natural compounds were 
queried in the standard SMILES format. Tanimoto similarities between compounds were 
computed with the Chemmine Similarity Workbench, which calculated maximum common 
substructure (MCS) similarities with the Tanimoto coefficient (Cao et al. 2008). Euclidean 
distance scores were calculated using Noncontiguous atom matching structural similarity 
function (NAMS) (Teixeira et al. 2013). The following formulas were used to calculate MCS 
similarity and TS score of natural compounds with Oxazolone and Oxazole ring substituted with 
a methyl group at the 2, 4 and 5 position. MCS similarity score: Atom number (AN) in MCS/AN 
in smaller molecule TS similarity score:  AN in MCS/ (AN in smaller molecule + AN in larger 
molecule –AN in MCS). Based on the results of the screening process, 2,5-Dihydro-2,4,5-
trimethyloxazole (TMO) with Tanimoto/Euclidean similarity score of 0.78/0.97 was selected as 
one of the natural compound for in vivo experiments. To further investigate the role of nitrogen 
and oxygen atoms of the oxazole ring and correlate them with colitogenic activity, 
Trimethylcyclopentane (TMC) and 2-Methyl-1-pyrroline (1MP) were selected as additional 
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controls. In addition, Vinclozolin was selected based on Euclidean distance score of 0.94 and 
widespread fungicide usage.            	  
 
Supplementary Figures 
Figure S1 (Refers to Figure 1). A minimal oxazole structure modulates intestinal epithelial 
transcriptional and antigen presentation capacity to invariant and non-variant NKT cells. 
A. Relative transcript abundance in MODE-K cells conditioned with the indicated compounds, 
normalized to β-actin. **p<0.01 (Student’s t-test). B. CD1d-restricted Interleukin 10 production in 
the absence of exogenous lipid supplementation in MODE-K cells conditioned with the indicated 
compounds followed by co-culture with B. invariant NKT (24.8) or C. non-invariant NKT (14S.6) 
hybridomas. ***p<0.001 (Student’s t-test). D. Interferon γ production in bone marrow derived 
dendritic cells conditioned with the indicated compounds followed by loading with α-galactosyl 
ceramide and co-cultured with 24.7 iNKT hybridoma. 
Figure S2 (Refers to Figure 1): A minimal oxazole structure does not alter CD1d protein 
expression or cellular distribution: Quantification of surface and intra-cellular CD1d protein 
expression in MODE-K cells conditioned with the indicated compounds for 48hr, as measured 
by A. flow cytometry and, B. relative proportions of intracellular and cell surface CD1d protein 
abundance. 
Figure S3 (refers to Figure 3): Intestinal inflammation, epithelial response and pathology 
to oxazole containing compounds does not require apriori host sensitization. A. 
Representative sections of wildtype animals administered 1% of the indicated compounds (50% 
EtOH v/v) by intra-rectal challenge and analyzed by H&E stain after 3 days. 10X magnification, 
scale bar (40 µM). Quantification of B. Mttp and C. Cyp1a1 transcripts (normalized to β-actin) 
from mucosal scrapings 2 days after intra-rectal challenge with 1% TMO, 1% TMC or EtOH 
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(50%v/v) vehicle (n=3). *p<0.05, ***p<0.001 (Student’s t-test). D. Animals were sensitized by 
topical application of the indicated compounds followed by intra-rectal administration of 1% 
TMO, 1% oxazolone, or EtOH (50% v/v) vehicle in wildtype C57Bl/6 animals. Quantitative colitis 
scoring was assessed on colons harvested 3 days after intra-rectal challenge. ***p<0.001 
(Student’s t-test). 
Figure S4 (refers to Figure 4): Aryl hydrocarbon receptor mediates expression of a 
subset of gene targets in response to oxazole containing compounds: MODE-K cells 
transfected with control or AhR specific siRNA, conditioned with the indicated compounds and 
relative transcript abundance was measured normalized to β-actin. A. cyp1a1, B. Ido1, C. Mttp  
***p<0.001 (Student’s t-test). 
Figure S4 (refers to Figure 4): Aryl hydrocarbon receptor attenuates CD1d-restricted 
responses in primary hepatocytes: Interleukin 10 production from primary hepatocytes 
derived from WT or AhR-deficient (KO) animals were conditioned with the indicated compounds, 
loaded with α-galactosyl ceramide followed by co-culture with 24.7 iNKT hybridoma. *** p<0.001 
(Student’s t-test). 
Figure S5 (Refers to STAR Methods): Synthesis of Frag-oz and Frag-tz. 
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Figure 1  
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure S1 
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Figure S2 
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Figure S3 
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Figure S4 
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Figure S6 
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Table S1: Oxazole-like structures identified by in silica screen against three chemical databases of naturally occurring compounds (Human Metabolome Database, Super Natural II database, Dictionary of Natural Compounds (Banerjee et al. 2015, Wishart et al 2007) using 3 parameters: Maximum Common Structure (MCS Similarity), Tanimoto similarity (Tc Similarity, Euclidean Distance Score. 
Chemical Name CAS/ Chemspider ID ( CID) Database
Column1 Column2 Column3 With Oxazolone With 5-Membered Oxazole Ring With Oxazolone4 With 5-Membered Oxazole Ring5 With Oxazolone6 With 5-Membered Oxazole Ring7 Source
2-Oxazolidinethione  2015027 ( CID) Dictionary of natural products 0.67 0.67 0.22 0.4 0.94 0.97 Food
4-Oxazolol  9882770 ( CID) Dictionary of natural products 0.83 0.83 0.29 0.56 0.95 0.98 N.A.
4,5-Dihydro-2-(2-hydroxyphenyl)-4-
oxazolecarboxylic acid  
13459647 ( CID) Dictionary of natural products 0.73 0.87
0.55 0.44 0.96 0.96 N.A.
4,5-Dihydro-2,5-diphenyloxazole  9588301 ( CID) Dictionary of natural products 0.69 0.87
0.5 0.39 0.95 0.97 N.A.
Aerucyclamide A  23342203 (CID) Dictionary of natural products 0.44 1 0.14 0.18 0.86 0.88 Microbes
Agrobactin  
20130128 (CID) 
Dictionary of natural products 0.69 1
0.21 0.17 0.89 0.94 Microbes
Allosamidin  106593 ( CID) Dictionary of natural products 0.37 0.87 0.1 0.11 0.91 0.95 Microbes
Almazolone  10481088 (CID) Dictionary of natural products 0.56 0.75 0.28 0.23 0.93 0.93 Microbes
Amychelin  28289083 ( CID) Dictionary of natural products 0.69 0.87 0.17 0.12 0.89 0.94 Microbes
Amythiamicin A  172053 ( CID) Dictionary of natural products 0.69 0.87 0.13 0.09 0.82 0.83 Microbes
Anachelin 10215353 (CID) Dictionary of natural products 0.69 0.87 0.17 0.12 0.86 0.91 Microbes
Ascidiacyclamide  143441 ( CID) Dictionary of natural products 0.5 1 0.11 0.13 0.88 0.9 Microbes
Carboxymycobactin T   4883340 (C ID) Dictionary of natural products 0.62 0.75 0.16 0.1 0.9 0.91 Microbes
Cladioxazole  10192495 ( CID) Dictionary of natural products 0.31 0.87 0.15 0.3 0.94 0.98 Microbes
Comoramide B 8684204 ( CID) Dictionary of natural products 0.44 0.87 0.1 0.12 0.88 0.9 Microbes
Cycloxazoline  140316 ( CID) Dictionary of natural products 0.44 1 0.12 0.17 0.92 0.95 Microbes
Didmolamide A  8432198 ( CID) Dictionary of natural products 0.5 1 0.16 0.19 0.88 0.9 Microbes
Dolastatin I  8273575 ( CID) Dictionary of natural products 0.5 0.87 0.16 0.17 0.85 0.87 Microbes
Fluvibactin  20129583 ( CID) Dictionary of natural products 0.69 1 0.21 0.17 0.89 0.94 Microbes
Indolmycin  182220 ( CID) Dictionary of natural products 0.44 0.75 0.23 0.25 0.91 0.94 Microbes
Leupyrrin C  10208508 ( CID) Dictionary of natural products 0.62 1 0.16 0.14 0.9 0.9 Microbes
Lissoclinamide 1  10355731 ( CID) Dictionary of natural products 0.5 1 0.12 0.14 0.86 0.88 Microbes
Mycobactin P 4952811 ( CID) Dictionary of natural products 0.44 0.87 0.1 0.11 0.88 0.89 Microbes
Nagelamide R  29214003 ( CID) Dictionary of natural products 0.62 0.87 0.18 0.14 0.87 0.88 Microbes
Nigribactin  29215280 ( CID) Dictionary of natural products 0.69 0.87 0.23 0.16 0.94 0.94 Microbes
Nocardichelin A  23284472 ( CID) Dictionary of natural products 0.68 0.87 0.19 0.13 0.89 0.93 Microbes
Oxachelin  28283771 ( CID) Dictionary of natural products 0.68 0.87 0.22 0.55 0.89 0.94 Microbes
Patellamide A  138571 ( CID) Dictionary of natural products 0.5 1 0.11 0.13 0.88 0.9 Microbes
Prepatellamide A  29212979 ( CID) Dictionary of natural products 0.5 0.87 0.12 0.11 0.87 0.9 Microbes
Raocyclamide A  9094062 ( CID) Dictionary of natural products 0.5 0.75 0.15 0.13 0.85 0.87 Microbes
Serratiochelin A  35523320 ( CID) Dictionary of natural products 0.68 1 0.29 0.24 0.94 0.94 Microbes
Shahidine  28285985 ( CID) Dictionary of natural products 0.68 0.87 0.4 0.3 0.94 0.96 Microbes
Spoxazomicin A  28288733 ( CID) Dictionary of natural products 0.68 0.87 0.35 0.26 0.89 0.94 Microbes
Ulicyclamide  8230874 ( CID) Dictionary of natural products 0.5 1 0.13 0.15 0.86 0.88 Microbes
Ulithiacyclamide  10263374 ( CID) Dictionary of natural products 0.5 1 0.12 0.14 0.87 0.89 Microbes
Vibriobactin  4575382 ( CID) Dictionary of natural products 0.44 0.75 0.11 0.1 0.89 0.89 Microbes
1-Hydroxy-3-methyl-9H-carbazole 14960-81-7 ( CAS) Human Metabolome 0.43 0.5 0.28 0.2 0.93 0.95 Food
2-Ethyl-4,5-dimethyloxazole  53833-30-0 ( CAS) Human Metabolome 0.78 0.75 0.39 0.54 0.92 0.94 Food
2-Isobutyl-4,5-dimethyloxazole  26131-91-9 ( CAS) Human Metabolome 0.63 0.75 0.35 0.46 0.91 0.94 Food
2,4-Dimethyloxazole 7208-05-1 ( CAS) Human Metabolome 0.86 0.86 0.35 0.67 0.92 0.95 Food
2,5-Dihydro-2,4-dimethyloxazole  77311-02-5 ( CAS) Human Metabolome 0.85 0.85 0.35 0.67 0.94 0.97 Food
2,5-Dimethyloxazole  23012-11-5 ( CAS) Human Metabolome 0.71 0.85 0.28 0.67 0.92 0.95 Food
4-Ethyl-5-methyl-2-(1-methylethyl)oxazole  84027-96-3 (  CAS) Human Metabolome 0.63 0.75 0.35 0.46 0.91 0.94 Food
4-Ethyl-5-methyl-2-propyloxazole   84027-94-1 ( CAS) Human Metabolome 0.63 0.75 0.35 0.46 0.91 0.94 N.A.
4,5-Dimethyl-2-(1-methylethyl)oxazole  19519-45-0 ( CAS) Human Metabolome 0.7 0.75 0.37 0.5 0.92 0.94 Food
4,5-Dimethyl-2-propyloxazole  53833-32-2 ( CAS) Human Metabolome 0.7 0.75 0.37 0.5 0.91 0.94 Food
4,5-Dimethyloxazole  20662-83-3 ( CAS) Human Metabolome 0.71 0.71 0.28 0.5 0.92 0.95 Food
5-Ethyl-4-methyl-2-(1-methylethyl)oxazole  102586-54-9 ( CAS) Human Metabolome 0.63 0.75 0.35 0.46 0.91 0.94 Food
5-Ethyl-4-methyloxazole   29584-92-7 ( CAS) Human Metabolome 0.62 0.62 0.26 0.45 0.92 0.95 Food
Methylhalfordinol  33864-03-8 ( CAS) Human Metabolome 0.68 0.75 0.46 0.29 0.91 0.92 Food
Trimethyloxazole 20662-84-4 ( CAS) Human Metabolome 0.75 0.75 0.33 0.6 0.92 0.95 Food
2,5-Dihydro-2,4,5-trimethyloxazole 22694-96-8 ( CAS) Human Metabolome/Toxcast 0.75 0.87 0.33 0.78 0.94 0.97 Food
(4E)-2-phenyl-4-(phenylmethylidene)-1,3-
oxazol-5-one 4648348 ( CID) Super Natural II 0.75 0.75 0.52 0.28 0.97 0.93 N.A.
(4E)-4-(3-Hydroxybenzylidene)-3-phenyl-
1,2-oxazol-5(4H)-one 1376002 ( CID) Super Natural II 0.5 0.5 0.28 0.17 0.97 0.91 N.A.
(4E)-4-(naphthalen-1-ylmethylidene)-2-
phenyl-1,3-oxazol-5-one 1266836 ( CID) Super Natural II 0.81 0.75 0.5 0.24 0.97 0.95 N.A.
(4E)-4-[(2,4-dimethylphenyl)methylidene]- 601096 ( CID) Super Natural II 0.81 0.75 0.54 0.26 0.97 0.95 N.A.
(4E)-4-[(4-{[(4Z)-5-oxo-2-phenyl-1,3-
oxazol-4-
ylidene]methyl}phenyl)methylidene]-2-
phenyl-1,3-oxazol-5-one 1645167 ( CID) Super Natural II 0.81 0.75 0.37 0.17 0.97 0.95 Food
(4E)-4-[(4-bromophenyl)methylidene]-2-
phenyl-1,3-oxazol-5-one 1266410 ( CID) Super Natural II 0.81 0.75 0.56 0.27 0.97 0.95 N.A.
(4E)-4-[(4-ethoxyphenyl)methylidene]-2-
phenyl-1,3-oxazol-5-one 583707 ( CID) Super Natural II 0.81 0.75 0.52 0.25 0.96 0.95 N.A.
(4E)-4-[(4-methoxyphenyl)methylidene]-2-
phenyl-1,3-oxazol-5-one
600847 ( CID) Super Natural II 0.81 0.75 0.54 0.26 0.97 0.95 N.A.
(4E)-4-[(4-methylphenyl)methylidene]-2- 617653 ( CID) Super Natural II 0.81 0.75 0.56 0.27 0.97 0.95 N.A.
2-phenyl-4-(propan-2-ylidene)-1,3-oxazol-
5-one 300575 (CID) Super Natural II 0.8 0.87 0.63 0.43 0.98 0.97 N.A.
4-(anthracen-9-ylmethylidene)-2-phenyl-  1424197 ( CID) Super Natural II 0.81 0.75 0.43 0.2 0.97 0.95 N.A.
Vinclozolin 36278 ( CID) Toxcast 0.37 0.62 0.21 0.24 0.91 0.94 Agriculture
Microcin B17 58107855 ( CID) Synthesized for manuscript 0.5 0.75 0.03 0.02 Microbes
Frag-oz Synthesized for manuscript 0.54 0.75 0.32 0.4 0.91 0.93 Microbes/Synthetic
Frag-tz Synthesized for manuscript 0.54 0.62 0.32 0.32 0.9 0.93 Microbes/Synthetic
Tc Similarity Euclidean Distance Score MCS Similarity
